Expertise in

conditions

Changhoon K. Yoo

Seoul, KR

Expertise in

conditions

Seoul, KR

OverviewLocationsClinical Research

Overview

Changhoon Yoo practices in Seoul, Republic of Korea. Yoo is highly rated in 12 conditions, according to our data. Their top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Gastrointestinal Stromal Tumor, Pancreatic Cancer, Pancreaticoduodenectomy, and Pancreatectomy.

Their clinical research consists of co-authoring 232 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Seoul, Republic of Korea

Other Locations

Ulsan, Republic of Korea

Songnam, Republic of Korea

Gyeonggi-do, Republic of Korea

Geumcheon, Republic of Korea

Gangneung, Republic of Korea

Chinju, 660701, Republic of Korea

Jungnam, 305764, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

Enrollment Status: Active_not_recruiting

Publish Date: August 06, 2025

Intervention Type: Drug

Study Drugs: Lutathera, Octreotide

Study Phase: Phase 3

A Study of Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Inoperable Locally Advanced or Metastatic Pancreatic Cancer

Enrollment Status: Active_not_recruiting

Publish Date: April 16, 2025

Intervention Type: Drug

Study Drug: Chlorphenesin Carbamate, Hydroxychloroquine

Study Phase: Phase 1

Multicenter Phase I/IIa Study of NASOX (Nal-IRI + S-1 + Oxaliplatin) as First-line Treatment for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Enrollment Status: Completed

Publish Date: January 28, 2025

Intervention Type: Drug

Study Drug: Nal-IRI, S-1, Oxaliplatin

Study Phase: Phase 1/Phase 2

Randomized Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin With or Without Durvalumab (MEDI4736) Followed by Postoperative Durvalumab (MEDI4736) in Patients With Localized Biliary Tract Cancer

Enrollment Status: Active_not_recruiting

Publish Date: January 28, 2025

Intervention Type: Drug

Study Drugs: Durvalumab, Gemcitabine, Cisplatin

Study Phase: Phase 2

Prospective Observational Study to Assess the Effectiveness and Safety of Lanreotide Autogel® in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Asia Region

Enrollment Status: Completed

Publish Date: January 28, 2025

Intervention Type: Drug

Randomized Phase 2 Study of mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Patients With Locally Advanced Pancreatic Adenocarcinoma

Enrollment Status: Active_not_recruiting

Publish Date: January 28, 2025

Intervention Type: Drug, Radiation

Study Drug: mFOLFIRINOX

Study Phase: Phase 2

A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer

Enrollment Status: Terminated

Publish Date: November 14, 2023

Intervention Type: Drug

Study Drugs: Bintrafusp Alfa, Gemcitabine, Cisplatin

Study Phase: Phase 2/Phase 3

A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy

Enrollment Status: Completed

Publish Date: October 25, 2023

Intervention Type: Drug

Study Drug: M7824

Study Phase: Phase 2

Phase II Trial of Regorafenib in Patients With Unresectable Hepatocellular Carcinoma After Progression on First Line Atezolizumab Plus Bevacizumab (REGONEXT Trial)

Enrollment Status: Unknown

Publish Date: April 26, 2023

Intervention Type: Drug

Study Drug: Regorafenib

Study Phase: Phase 2

Phase II Study of Regorafenib-nivolumab Combination Therapy for Chemotherapy-naïve Patients With Unresectable or Metastatic Hepatocellular Carcinoma

Enrollment Status: Completed

Publish Date: December 06, 2022

Intervention Type: Drug

Study Drug: Regorafenib/Nivolumab

Study Phase: Phase 2

Randomized Phase II Trial of Fluorouracil and Folinic Acid With or Without Liposomal Irinotecan (ONIVYDE) for Patients With Metastatic Biliary Tract Cancer Which Progressed Following Gemcitabine Plus Cisplatin

Enrollment Status: Completed

Publish Date: August 24, 2022

Intervention Type: Drug

Study Phase: Phase 2

The Pilot Study of Trastuzumab in Combination With Gemcitabine Plus Cisplatin for HER2-positive Biliary Tract Cancer

Enrollment Status: Completed

Publish Date: January 05, 2021

Intervention Type: Drug

Study Phase: Phase 2

Multicenter Retrospective Analysis for Efficacy and Safety of Second-Line Nab-Paclitaxel Plus Gemcitabine After Progression on 1st-line FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma

Enrollment Status: Completed

Publish Date: March 13, 2020

Intervention Type: Drug

View 12 Less Clinical Trials

232 Total Publications

Predicting Chemotherapy Response in Patients With Advanced or Metastatic Pancreatic Cancer Using Machine Learning.

Journal: JCO clinical cancer informatics

Published: December 02, 2025

View All 232 Publications

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yoo's expertise for a condition

ConditionClose